PRESS RELEASE

Q4 2022 — Press release

Q4 2022PDF · 14 pages288 KB
News Release
____________________________________________________________________________
FOR IMMEDIATE RELEASE
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
- 	Fourth-Quarter and Full-Year 2022 Results Reflect Sustained Strong Revenue Growth
- 	Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From
Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8%
- 	Fourth-Quarter 2022 GAAP EPS From Continuing Operations Was $1.18; Fourth-
Quarter 2022 Non-GAAP EPS Was $1.62
- 	Full-Year 2022 Worldwide Sales Were $59.3 Billion, an Increase of 22% From Full Year
2021; Growth Excluding LAGEVRIO Was 12%; Growth Excluding LAGEVRIO and the
Impact of Foreign Exchange Was 15%
o 	KEYTRUDA Sales Grew 22% to $20.9 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 27%
o 	GARDASIL/GARDASIL 9 Sales Grew 22% to $6.9 Billion; Excluding the Impact
of Foreign Exchange, Sales Grew 27%
- 	Full-Year 2022 GAAP EPS From Continuing Operations Was $5.71; Full-Year 2022
Non-GAAP EPS Was $7.48
- 	In 2022, Augmented Pipeline Through Strategic Business Development, Including
Acquisition of Imago and Key Agreements With Moderna, Orna, Orion and Kelun-
Biotech
- 	2023 Financial Outlook
o 	Anticipates Full-Year 2023 Worldwide Sales To Be Between $57.2 Billion and
$58.7 Billion; Outlook Includes Approximately $1.0 Billion of LAGEVRIO Sales
o 	Expects Full-Year 2023 GAAP EPS To Be Between $5.86 and $6.01; Expects
Non-GAAP EPS To Be Between $6.80 and $6.95
RAHWAY, N.J., Feb. 2, 2023 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the fourth quarter and full year of 2022.
"2022 was an exceptional year for Merck, which is a testament to the profound impact
our medicines and vaccines are having on patients globally," said Robert M. Davis, chairman
and chief executive officer. “I am extremely proud of what our talented and dedicated colleagues
have accomplished scientifically, commercially and operationally. Our science-led strategy is
working as we continue to build a sustainable engine that will drive innovation and generate
long-term value for patients and shareholders well into the next decade.”
Financial Summary
Financial information presented in this release reflects Merck’s results on a continuing
operations basis, which excludes Organon & Co. that was spun off in 2021.

-- 1 of 14 --

- 2 -
$ in millions,
except EPS
amounts
Fourth Quarter 	Year Ended
2022 	2021 	Change
Change Ex-
Exchange
Dec. 31,
2022
Dec. 31,
2021 	Change
Change Ex-
Exchange
Sales 	$13,830 	$13,521 	2% 	8% 	$59,283 	$48,704 	22% 	26%
GAAP net
income1 	3,017 	3,820 	-21% 	-17% 	14,519 	12,345 	18% 	21%
Non-GAAP net
income that
excludes
certain
items 1,2 * 	4,129 	4,592 	-10% 	-7% 	19,005 	13,623 	40% 	43%
GAAP EPS 	1.18 	1.51 	-22% 	-17% 	5.71 	4.86 	17% 	21%
Non-GAAP
EPS that
excludes
certain items2* 	1.62 	1.81 	-10% 	-7% 	7.48 	5.37 	39% 	43%
*Refer to table on page 11.
Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming
dilution was $1.18 for the fourth quarter and $5.71 for the full year of 2022. Non-GAAP EPS was
$1.62 for the fourth quarter and $7.48 for the full year of 2022. The declines in GAAP and non-
GAAP EPS in the fourth quarter versus the prior year were primarily due to lower fourth quarter
2021 effective tax rates and the unfavorable impact of foreign exchange, partially offset by
strong underlying business performance. The GAAP EPS decline in the fourth quarter also
reflects the unfavorable impact of losses from investments in equity securities compared with
gains in the prior year. Full-year 2022 and 2021 GAAP and non-GAAP EPS were negatively
impacted by $0.22 and $0.65, respectively, related to an asset acquisition, and collaboration
and licensing agreements.
Non-GAAP EPS excludes acquisition- and divestiture-related costs (including pretax
intangible asset impairment research and development [R&D] charges of $780 million and $1.7
billion in the fourth quarter and full year of 2022, respectively, largely related to nemtabrutinib)
and restructuring costs, as well as income and losses from investments in equity securities.
In 2022, the company changed the treatment of certain items for purposes of its non-
GAAP reporting. Results for 2021 have been recast to conform to the new presentation. For
more information, refer to the Form 8-K filed by the company on April 21, 2022.
1 Net income from continuing operations attributable to Merck & Co., Inc.
2 Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a
attached to this release. Non-GAAP results for 2021 have been recast to conform to presentation changes implemented in 2022.

-- 2 of 14 --

- 3 -
Oncology Program Highlights
• 	Merck announced the following regulatory and clinical milestones for KEYTRUDA
(pembrolizumab), Merck’s anti-PD-1 therapy:
o 	KEYTRUDA approved by the U.S. Food and Drug Administration (FDA) as
adjuvant treatment following resection and platinum-based chemotherapy for
adult patients with stage IB (T2a ≥4 centimeters), II, or IIIA non-small cell lung
cancer (NSCLC), based on the pivotal Phase 3 KEYNOTE-091 trial.
o 	In collaboration with Moderna, Inc. (Moderna), positive topline results from the
Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, which showed that
KEYTRUDA in combination with mRNA-4157/V940, an investigational
personalized mRNA therapeutic cancer vaccine, demonstrated a statistically
significant and clinically meaningful improvement in the primary endpoint of
recurrence-free survival versus KEYTRUDA alone for the adjuvant treatment of
patients with stage III/IV melanoma following complete resection.
o 	In collaboration with Seagen Inc. and Astellas Pharma Inc., acceptance by the
FDA for priority review of the supplemental Biologics License Application for
KEYTRUDA in combination with Padcev®3 (enfortumab vedotin-ejfv) for the
treatment of patients with locally advanced or metastatic urothelial cancer who
are not eligible to receive cisplatin-containing chemotherapy.
o 	Positive topline results from the pivotal Phase 3 KEYNOTE-859 trial investigating
KEYTRUDA in combination with chemotherapy for the first-line treatment of
patients with human epidermal growth factor receptor 2 (HER2)-negative locally
advanced unresectable or metastatic gastric or gastroesophageal junction
adenocarcinoma.
o 	Positive topline results from the Phase 3 KEYNOTE-966 trial investigating
KEYTRUDA in combination with standard of care chemotherapy (gemcitabine
and cisplatin) for the first-line treatment of patients with advanced or
unresectable biliary tract cancer.
• 	Merck announced that Lynparza (olaparib), an oral PARP inhibitor being co-developed
and co-commercialized with AstraZeneca, was approved in the European Union (EU) in
combination with abiraterone and prednisone or prednisolone for the treatment of adult
patients with metastatic castration-resistant prostate cancer in whom chemotherapy is
not clinically indicated, based on the Phase 3 PROpel trial.
Vaccine Program Highlights
• 	Merck announced that an updated systematic literature review of 138 peer-reviewed
studies observed that use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6,
11, 16 and 18) Vaccine, Recombinant] led to reductions in the rates of high-grade
(precancerous) and low-grade cervical lesions, as well as reductions in certain non-
cervical HPV-related diseases and HPV infection in women and men.
3 Registered trademark of Seagen and Agensys.

-- 3 of 14 --

- 4 -
Cardiovascular Program Highlights
• 	Merck will present results from the Phase 3 STELLAR study evaluating investigational
sotatercept for the treatment of patients with pulmonary arterial hypertension, and from
the Phase 2 study evaluating MK-0616, the company’s investigational oral macrocyclic
peptide PCSK9 inhibitor for the treatment of patients with hypercholesterolemia, at the
American College of Cardiology’s 72nd Annual Scientific Session together with the
World Heart Federation’s World Congress of Cardiology (ACC.23/WCC). Merck will host
an investor event at ACC.23/WCC on March 6, 2023, to discuss these results. Further
details will be announced at a later date.
Business Development Highlights
• 	Merck announced and successfully completed the acquisition of Imago BioSciences, Inc.
(Imago), for an approximate total equity value of $1.35 billion, expanding Merck’s
growing hematology portfolio.
• 	Merck announced that it has expanded its relationship and entered into an exclusive
license and collaboration agreement with Kelun-Biotech (a holding subsidiary of Sichuan
Kelun Pharmaceutical Co., Ltd) to develop up to seven investigational preclinical
antibody-drug conjugates (ADCs) for the treatment of cancer.
Environmental, Social and Governance (ESG) Updates
• 	Merck was named one of America’s most JUST companies by JUST Capital and CNBC,
ranking No. 1 in the pharmaceuticals and biotech industry for the third straight year and
No. 26 overall of all companies named.
• 	Merck published its Sustainability Bond Allocation Report, which highlighted how the
company’s initial $1.0 billion sustainability bond is helping to drive progress across ESG
focus areas.

-- 4 of 14 --

- 5 -
Fourth-Quarter and Full-Year Revenue Performance
The following table reflects sales of the company’s top pharmaceutical products, as well
as sales of Animal Health products.
$ in millions 	Fourth Quarter 	Year Ended
2022 	2021 	Change
Change Ex-
Exchange
Dec. 31,
2022
Dec. 31,
2021 	Change
Change Ex-
Exchange
Total Sales 	$13,830 	$13,521 	2% 	8% 	$59,283 	$48,704 	22% 	26%
Pharmaceutical 	12,180 	12,039 	1% 	9% 	52,005 	42,754 	22% 	28%
KEYTRUDA 	5,450 	4,577 	19% 	26% 	20,937 	17,186 	22% 	27%
GARDASIL /
GARDASIL 9 	1,470 	1,528 	-4% 	6% 	6,897 	5,673 	22% 	27%
LAGEVRIO 	825 	952 	-13% 	2% 	5,684 	952 	*** 	***
JANUVIA /
JANUMET 	913 	1,393 	-34% 	-29% 	4,513 	5,288 	-15% 	-9%
PROQUAD, M-M-R
II and VARIVAX 	526 	509 	3% 	6% 	2,241 	2,135 	5% 	7%
BRIDION 	441 	436 	1% 	7% 	1,685 	1,532 	10% 	16%
Lynparza* 	292 	268 	9% 	14% 	1,116 	989 	13% 	18%
Lenvima* 	216 	206 	5% 	9% 	876 	704 	24% 	28%
ROTATEQ 	139 	213 	-35% 	-31% 	783 	807 	-3% 	0%
SIMPONI 	166 	206 	-19% 	-8% 	706 	825 	-14% 	-4%
Animal Health 	1,230 	1,261 	-2% 	6% 	5,550 	5,568 	0% 	6%
Livestock 	814 	791 	3% 	12% 	3,300 	3,295 	0% 	7%
Companion
Animals 	416 	470 	-11% 	-5% 	2,250 	2,273 	-1% 	4%
Other Revenues** 	420 	221 	90% 	-25% 	1,728 	382 	*** 	87%
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including revenue-hedging activities.
***>100%
Pharmaceutical Revenue
Fourth-quarter pharmaceutical sales grew 1% to $12.2 billion. Excluding the unfavorable
impact of foreign exchange, pharmaceutical sales grew 9%, primarily driven by oncology and
hospital acute care, partially offset by diabetes.
Growth in oncology was largely driven by higher sales of KEYTRUDA, which rose 19%
to $5.5 billion in the quarter. Global sales growth of KEYTRUDA reflects continued strong
momentum from metastatic indications including certain types of NSCLC, renal cell carcinoma,
head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC) and
microsatellite instability-high (MSI-H) cancers, and increased uptake across recent earlier-stage
launches, including certain types of neoadjuvant/adjuvant TNBC in the U.S. Also contributing to
growth in oncology was increased alliance revenue from Lynparza, which grew 9% to $292
million, driven primarily by higher demand in the U.S. In addition, sales of WELIREG
(belzutifan), an oral hypoxia-inducible factor-2 alpha inhibitor, increased to $40 million due to
continued uptake in the U.S. following the product’s launch in 2021.
Growth in hospital acute care reflects higher sales of ZERBAXA (ceftolozane and
tazobactam), a combination cephalosporin antibacterial and beta-lactamase inhibitor for the
treatment of patients with certain bacterial infections. ZERBAXA sales of $49 million in the
fourth quarter of 2022 increased from $10 million in the fourth quarter of 2021, reflecting uptake

-- 5 of 14 --

- 6 -
from the completion of the phased resupply in 2022 that was initiated in the fourth quarter of
2021. Growth in hospital acute care also reflects higher sales of PREVYMIS (letermovir), a
medicine for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of
an allogenic hematopoietic stem cell transplant, which increased 17% to $118 million, reflecting
higher demand globally.
Vaccines sales performance reflects lower combined sales of GARDASIL and
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to prevent
certain cancers and other diseases caused by HPV, which declined 4% to $1.5 billion.
Excluding the unfavorable impact of foreign exchange, GARDASIL/GARDASIL 9 sales grew
6%, reflecting higher demand outside of the U.S., particularly in China. Vaccines sales
performance also reflects lower sales of PNEUMOVAX 23 (pneumococcal vaccine polyvalent),
a vaccine to help prevent pneumococcal disease, which declined 50% to $145 million, primarily
reflecting lower U.S. demand as the market continues to shift toward newer adult pneumococcal
conjugate vaccines. In addition, sales of ROTATEQ (Rotavirus Vaccine, Live Oral, Pentavalent),
a vaccine to help protect against rotavirus gastroenteritis in infants and children, declined 35%
to $139 million, primarily due to lower sales in China, which benefited in the fourth quarter of
2021 from increased supply, and lower sales in the U.S. largely due to the timing of public-
sector purchases. Vaccines sales performance benefited from the ongoing pediatric launch of
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine), a vaccine to help prevent
invasive pneumococcal disease, which had sales of $138 million, largely due to inventory
stocking in the U.S.
Pharmaceutical sales growth was partially offset by lower combined sales of JANUVIA
(sitagliptin) and JANUMET (sitagliptin and metformin HCI), for the treatment of type 2 diabetes,
which declined 34% to $913 million, primarily reflecting generic competition in certain
international markets, particularly in Europe and the Asia Pacific region, and lower demand and
net pricing in the U.S.
Sales of LAGEVRIO (molnupiravir), an investigational oral antiviral COVID-19 medicine,
decreased 13% to $825 million. Excluding the unfavorable impact of foreign exchange, sales
increased 2%, primarily driven by strong growth in Japan and the U.K. and the launch in
Australia, offset by a decline in the U.S.
Full-year 2022 pharmaceutical sales grew 22% to $52.0 billion. Pharmaceutical sales
growth was 16% excluding LAGEVRIO and the unfavorable impact of foreign exchange,
primarily driven by higher sales in oncology, particularly KEYTRUDA, higher sales of vaccines,
reflecting strong growth of GARDASIL/GARDASIL 9 and the ongoing pediatric launch of
VAXNEUVANCE, as well as growth in hospital acute care products, including ZERBAXA and
BRIDION (sugammadex) injection 100 mg/mL, a medicine for the reversal of neuromuscular
blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric
patients ages 2 years and older undergoing surgery. Pharmaceutical sales growth in 2022 was
partially offset by lower sales of JANUVIA and JANUMET, primarily reflecting lower demand in
Europe as a result of generic competition, and a decline in PNEUMOVAX 23 sales as the U.S.
market continues to shift toward newer adult pneumococcal conjugate vaccines. COVID-19-

-- 6 of 14 --

- 7 -
related disruptions negatively affected sales in 2022, but to a lesser extent than in 2021, which
benefited year-over-year sales growth.
Animal Health Revenue
Animal Health sales totaled $1.2 billion for the fourth quarter of 2022, a 2% decline
compared with the fourth quarter of 2021. Excluding the unfavorable effect of foreign exchange,
Animal Health sales increased 6%. Sales growth of livestock products reflects higher demand,
notably in the ruminant and poultry product portfolio, which includes technology solutions
products, as well as higher pricing. Sales of companion animal products were negatively
impacted by a reduction in veterinary visits in the broader companion animal market following
the more favorable trend during the pandemic, as well as supply constraints for certain
vaccines, partially offset by higher pricing.
Full-year 2022 Animal Health sales were $5.5 billion, in line with the prior year.
Excluding the unfavorable effect of foreign exchange, Animal Health sales grew 6%, primarily
due to higher pricing. Full-year sales growth was also driven by higher demand of livestock
products, led by ruminant, poultry and swine products. Sales of companion animal products also
reflect higher demand for the BRAVECTO (fluralaner) parasiticide line of products, which had
sales of $1.0 billion, partially offset by supply constraints for certain vaccines.
Fourth-Quarter and Full-Year Expense, EPS and Related Information
The tables below present selected expense information.
$ in millions
Fourth Quarter 2022 	GAAP
Acquisition-
and
Divestiture-
Related Costs4
Restructuring
Costs
(Income) Loss
From
Investments in
Equity
Securities
Certain
Other
Items
Non-
GAAP2
Cost of sales 	$3,881 	$482 	$38 	$- 	$- 	$3,361
Selling, general and
administrative 	2,687 	39 	20 	- 	- 	2,628
Research and development 	3,775 	740 	- 	- 	- 	3,035
Restructuring costs 	49 	- 	49 	- 	- 	-
Other (income) expense, net 	(75) 	(69) 	- 	80 	- 	(86)
Fourth Quarter 2021
Cost of sales 	$3,873 	$419 	$47 	$- 	$(4) 	$3,411
Selling, general and
administrative 	2,830 	226 	10 	- 	- 	2,594
Research and development 	3,068 	397 	7 	- 	- 	2,664
Restructuring costs 	174 	- 	174 	- 	- 	-
Other (income) expense, net 	(333) 	(3) 	- 	(381) 	- 	51

-- 7 of 14 --

- 8 -
$ in millions
Year Ended Dec. 31, 2022 	GAAP
Acquisition-
and
Divestiture-
Related Costs4
Restructuring
Costs
(Income) Loss
From
Investments in
Equity
Securities
Certain
Other
Items
Non-
GAAP2
Cost of sales 	$17,411 	$2,059 	$205 	$- 	$- 	$15,147
Selling, general and
administrative 	10,042 	176 	94 	- 	- 	9,772
Research and development 	13,548 	1,676 	30 	- 	- 	11,842
Restructuring costs 	337 	- 	337 	- 	- 	-
Other (income) expense, net 	1,501 	(207) 	- 	1,348 	- 	360
Year Ended Dec. 31, 2021
Cost of sales 	$13,626 	$1,607 	$160 	$- 	$221 	$11,638
Selling, general and
administrative 	9,634 	322 	19 	- 	- 	9,293
Research and development 	12,245 	479 	28 	- 	- 	11,738
Restructuring costs 	661 	- 	661 	- 	- 	-
Other (income) expense, net 	(1,341) 	76 	- 	(1,884) 	- 	467
GAAP Expense, EPS and Related Information
Gross margin was 71.9% for the fourth quarter of 2022 compared with 71.4% for the
fourth quarter of 2021. The increase primarily reflects favorable product mix and foreign
exchange. Gross margin was 70.6% for the full year of 2022 compared to 72.0% for the full year
of 2021. The decline primarily reflects the unfavorable impacts of higher amortization of
intangible assets, as well as higher revenue from third-party manufacturing arrangements and
sales of LAGEVRIO, both of which have lower gross margins. The full-year gross margin
decline was partially offset by the favorable effects of product mix, foreign exchange and
charges in the prior year related to the discontinuation of COVID-19 development programs.
Selling, general and administrative (SG&A) expenses were $2.7 billion in the fourth
quarter of 2022, a decrease of 5% compared to the fourth quarter of 2021. The decrease
primarily reflects lower acquisition- and divestiture-related costs and the favorable effect of
foreign exchange, partially offset by higher promotional spending, as well as higher
administrative costs. Full-year SG&A expenses were $10.0 billion, an increase of 4% compared
to the full year of 2021. The increase primarily reflects higher administrative costs, as well as
higher promotional spending, partially offset by the favorable impact of foreign exchange and
lower acquisition- and divestiture-related costs.
R&D expenses were $3.8 billion in the fourth quarter of 2022, an increase of 23%
compared to the fourth quarter of 2021. The increase was primarily driven by higher intangible
asset impairment charges related to nemtabrutinib, which were $780 million in the fourth quarter
of 2022 compared with $275 million in the fourth quarter of 2021, lower reimbursement of
4 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a
result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value
measurement of liabilities for contingent consideration. R&D expenses include intangible asset impairment charges of $780 million
and $1.7 billion in fourth quarter and full year 2022, respectively, and $275 million in both fourth quarter and full year 2021, largely
related to nemtabrutinib, which was obtained as part of the 2020 acquisition of ArQule, Inc. Also includes integration, transaction
and certain other costs related to acquisitions and divestitures.

-- 8 of 14 --

- 9 -
LAGEVRIO R&D costs from Ridgeback Biotherapeutics (Ridgeback), higher compensation and
benefit costs reflecting in part increased headcount to support expanded clinical development
activity, and higher clinical development spending. R&D expenses were $13.5 billion for the full
year of 2022, an increase of 11% compared with the full year of 2021. The increase was
primarily driven by higher intangible asset impairment charges, which were $1.7 billion in 2022
compared with $275 million in 2021, largely related to nemtabrutinib, $690 million of charges in
2022 related to collaboration and licensing agreements with Moderna, Orna Therapeutics
(Orna) and Orion Corporation (Orion), as well as higher compensation and benefit costs and
clinical development spending. The increase was partially offset by a $1.7 billion charge in the
prior year for the acquisition of Pandion Therapeutics, Inc. (Pandion).
Other (income) expense, net, was $75 million of income in the fourth quarter of 2022
compared to $333 million of income in the fourth quarter of 2021. Other (income) expense, net,
was $1.5 billion of expense in the full year of 2022 compared to $1.3 billion of income in the full
year of 2021. The change in both periods is primarily due to net losses from investments in
equity securities in 2022 compared with net gains from investments in equity securities in 2021.
The effective tax rate for the fourth quarter of 2022 of 14.1% reflects the unfavorable
impact of a higher than anticipated full-year rate of 11.7% due to a less favorable mix of income
and expense than previously anticipated, while the effective tax rate for the fourth quarter of
2021 of 2.2% reflects the favorable impact of a lower than previously expected full-year 2021
rate of 11.0%.
GAAP EPS was $1.18 for the fourth quarter of 2022 compared to $1.51 for the fourth
quarter of 2021. GAAP EPS was $5.71 for the full year of 2022 compared to $4.86 for the full
year of 2021.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 75.7% for the fourth quarter of 2022 compared to 74.8%
for the fourth quarter of 2021. The increase primarily reflects the favorable effects of product mix
and foreign exchange. Non-GAAP gross margin was 74.4% for the full year of 2022 compared
to 76.1% for the full year of 2021. The decrease primarily reflects the impact of higher revenue
from third-party manufacturing arrangements and sales of LAGEVRIO, both of which have lower
gross margins, partially offset by the favorable effects of product mix and foreign exchange.
Non-GAAP SG&A expenses were $2.6 billion in the fourth quarter of 2022, an increase
of 1% compared to the fourth quarter of 2021. Non-GAAP SG&A expenses for the full year were
$9.8 billion, an increase of 5% compared to the full year of 2021. The increase in both periods
primarily reflects higher administrative costs, as well as higher promotional spending, partially
offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $3.0 billion in the fourth quarter of 2022, an increase of
14% compared with the fourth quarter of 2021. The increase was primarily driven by lower
reimbursement of LAGEVRIO R&D costs from Ridgeback, higher compensation and benefit
costs reflecting in part increased headcount to support expanded clinical development activity,

-- 9 of 14 --

- 10 -
and higher clinical development spending. Non-GAAP R&D expenses were $11.8 billion for the
full year of 2022, an increase of 1% compared with the full year of 2021. The increase was
primarily driven by $690 million of charges in 2022 related to collaboration and licensing
agreements with Moderna, Orna and Orion, as well as higher compensation and benefit costs
and clinical development spending. The increase was partially offset by a $1.7 billion charge in
the prior year for the acquisition of Pandion.
Non-GAAP other (income) expense, net, was $86 million of income in the fourth quarter
of 2022 compared to $51 million of expense in the fourth quarter of 2021. Non-GAAP other
(income) expense, net, was $360 million of expense in the full year of 2022 compared to $467
million of expense in the full year of 2021.
The non-GAAP effective tax rate for the fourth quarter of 2022 of 15.6% reflects the
unfavorable impact of a higher than anticipated full-year rate of 14.2% due to a less favorable
mix of income and expense than previously anticipated, while the non-GAAP effective tax rate
for the fourth quarter of 2021 of 4.3% reflects the favorable impact of a lower than previously
expected full-year 2021 rate of 12.4%.
Non-GAAP EPS was $1.62 for the fourth quarter of 2022 compared to $1.81 for the
fourth quarter of 2021. Non-GAAP EPS was $7.48 for the full year of 2022 compared to $5.37
for the full year of 2021.
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.

-- 10 of 14 --

- 11 -
Financial Outlook
The following table summarizes the company’s full-year 2023 financial guidance.
GAAP 	Non-GAAP2
Revenue* 	$57.2 to $58.7 billion 	$57.2 to $58.7 billion
Gross margin 	Approximately 73% 	Approximately 77%
Operating expenses** 	$23.3 to $24.3 billion 	$23.1 to $24.1 billion
Effective tax rate 	17% to 18% 	17% to 18%
EPS*** 	$5.86 to $6.01 	$6.80 to $6.95
*Includes approximately $1.0 billion of LAGEVRIO sales. The company does not have any non-GAAP adjustments to revenue.
**Includes an aggregate $1.4 billion of R&D expenses related to the Imago acquisition and upfront payment for a license and
collaboration agreement with Kelun-Biotech.
***Includes $0.53 of charges related to the Imago acquisition and upfront payment to Kelun-Biotech. EPS guidance for 2023
assumes a share count (assuming dilution) of approximately 2.55 billion shares.
Merck anticipates full-year 2023 revenue to be between $57.2 billion and $58.7 billion,
including a negative impact of foreign exchange of approximately 2% at mid-January 2023
exchange rates. The company expects a significant decline in sales of LAGEVRIO, which are
expected to be approximately $1.0 billion.
Merck expects full-year 2023 GAAP EPS to be between $5.86 and $6.01.
5 Includes the estimated tax impact on the reconciling items. In addition, the amount for full-year 2021 includes a $207 million net tax
benefit related to the settlement of certain federal income tax matters.
$ in millions, except EPS amounts 	Fourth Quarter 	Year Ended
2022 	2021 	Dec. 31, 2022 	Dec. 31, 2021
EPS
GAAP EPS 	$1.18 	$1.51 	$5.71 	$4.86
Difference 	0.44 	0.30 	1.77 	0.51
Non-GAAP EPS that excludes items listed below2 	$1.62 	$1.81 	$7.48 	$5.37
Net Income
GAAP net income1 	$3,017 	$3,820 	$14,519 	$12,345
Difference 	1,112 	772 	4,486 	1,278
Non-GAAP net income that excludes items listed
below1,2 	$4,129 	$4,592 	$19,005 	$13,623
Decrease (Increase) in Net Income Due to
Excluded Items:
Acquisition- and divestiture-related costs 4 	$1,192 	$1,039 	$3,704 	$2,484
Restructuring costs 	107 	238 	666 	868
Loss (income) from investments in equity
securities 	80 	(381) 	1,348 	(1,884)
Charges for the discontinuation of
COVID-19 development programs 	- 	- 	- 	221
Other 	- 	(4) 	- 	-
Net decrease (increase) in income before taxes 	1,379 	892 	5,718 	1,689
Income tax (benefit) expense5 	(267) 	(120) 	(1,232) 	(411)
Decrease (increase) in net income 	$1,112 	$772 	$4,486 	$1,278

-- 11 of 14 --

- 12 -
Merck expects full-year 2023 non-GAAP EPS to be between $6.80 and $6.95, including
a negative impact of foreign exchange of approximately 4%. The non-GAAP range excludes
acquisition- and divestiture-related costs, costs related to restructuring programs, as well as
income and losses from investment in equity securities.
In the fourth quarter of 2022, Merck announced the acquisition of Imago for an
approximate total value of $1.35 billion and a license and collaboration agreement with Kelun-
Biotech, which includes an upfront payment of $175 million. The Imago acquisition closed in
January 2023 and the collaboration with Kelun-Biotech is expected to close in the first quarter of
2023, resulting in the inclusion of an aggregate $1.4 billion of R&D expenses in Merck’s GAAP
and non-GAAP results for the first quarter and full year of 2023. The Imago acquisition is also
anticipated to result in an approximate 1 percentage point unfavorable impact to Merck’s
expected full-year 2023 GAAP and non-GAAP tax rates. The impact of these two transactions
on expected full-year 2023 GAAP and non-GAAP EPS is approximately $0.53. GAAP and non-
GAAP EPS in 2022 were negatively impacted by $0.22 of charges related to the collaboration
and licensing agreements with Moderna, Orna and Orion.
Operating expenses include incremental R&D spending to advance the development of
the Imago and Kelun-Biotech programs, as well as other promising programs related to the
collaboration and licensing agreements with Moderna, Orna and Orion.
The financial outlook does not assume additional significant potential business
development transactions.
A reconciliation of anticipated 2023 GAAP EPS to non-GAAP EPS and the items
excluded from non-GAAP EPS are provided in the table below.
$ in millions, except EPS amounts 	Full Year 2023
GAAP EPS 	$5.86 to $6.01
Difference 	$0.94
Non-GAAP EPS that excludes items listed below2 	$6.80 to $6.95
Acquisition- and divestiture-related costs
Restructuring costs
(Income) loss from investments in equity securities
$2,500
400
(20)
Net decrease (increase) in income before taxes 	$2,880
Estimated income tax (benefit) expense 	(480)
Decrease (increase) in net income 	$2,400
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Thursday, Feb. 2, at 8:00 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (888) 769-8514 (U.S. Toll-Free) or (517) 308-
9208 (International) and using the access code 8206435.

-- 12 of 14 --

- 13 -
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the
impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of international economies
and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021,
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).
###

-- 13 of 14 --

- 14 -
Media Contacts: 	Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
Peter Dannenbaum
(908) 740-1037
peter.dannenbaum@merck.com
Steven Graziano
(908) 740-6582
steven.graziano@merck.com

-- 14 of 14 --